The Landscape of Immunotherapy Resistance in NSCLC
Lung cancer is the leading cause of cancer mortality worldwide. Immunotherapy has demonstrated clinically significant benefit for non-small-cell lung cancer, but innate (primary) or acquired resistance remains a challenge. Criteria for a uniform clinical definition of acquired resistance have been r...
| Published in: | Frontiers in Oncology |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.817548/full |